News

Airway Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced that the European Medicines Agency

Viatris Inc, a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia

Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients

Ono Pharmaceutical Co., Ltd. today announced that it has entered into a definitive agreement with Seikagaku Corporation (Tokyo, Japan, President and CEO: Ken Mizutani; “Seikagaku”), based on the discussions held related to co-development and marketing collaboration on Gel-One under development

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of adult

Dizal a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation

MetaVia Inc. a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-driven

Porosome Therapeutics, Inc. today announced key advancements in its first-in-class, disease-modifying neurological platform, which will transform Alzheimer’s Disease (AD) research and treatment by offering

Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic

Dyne Therapeutics, Inc. a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the U.S. Food and Drug Administration